Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Tonix Pharmaceuticals Holding Corp’s stock clocked out at $29.90, up 12.41% from its previous closing price of $26.60. In other words, the price has increased by $12.41 from its previous closing price. On the day, 1.5 million shares were traded. TNXP stock price reached its highest trading level at $30.74 during the session, while it also had its lowest trading level at $25.11.
Ratios:
To gain a deeper understanding of TNXP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.64 and its Current Ratio is at 12.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 15 ’25 when LEDERMAN SETH bought 4,000 shares for $21.55 per share. The transaction valued at 86,200 led to the insider holds 4,005 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 219007632 and an Enterprise Value of 32828366. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.81 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 3.252 whereas that against EBITDA is -0.442.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.85, which has changed by -0.95082235 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $659.20, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is 55.21%, while the 200-Day Moving Average is calculated to be 37.02%.
Shares Statistics:
It appears that TNXP traded 1.34M shares on average per day over the past three months and 999080 shares per day over the past ten days. A total of 7.32M shares are outstanding, with a floating share count of 7.32M. Insiders hold about 0.07% of the company’s shares, while institutions hold 6.78% stake in the company. Shares short for TNXP as of 1745971200 were 976171 with a Short Ratio of 0.73, compared to 1743379200 on 919908. Therefore, it implies a Short% of Shares Outstanding of 976171 and a Short% of Float of 14.19.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is -$4.67, with 1 analysts recommending between -$4.67 and -$4.67.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $2.6M. It ranges from a high estimate of $2.6M to a low estimate of $2.6M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.21MFor the next quarter, 1 analysts are estimating revenue of $2.7M. There is a high estimate of $2.7M for the next quarter, whereas the lowest estimate is $2.7M.
A total of 1 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $10.6M, while the lowest revenue estimate was $10.6M, resulting in an average revenue estimate of $10.6M. In the same quarter a year ago, actual revenue was $10.09MBased on 2 analysts’ estimates, the company’s revenue will be $98.7M in the next fiscal year. The high estimate is $166.1M and the low estimate is $31.3M.
